Results of the XPAND Australia postmarketing study confirm bench testing results which demonstrated an improved permeation rate of 0.4cc per day. The expander is labeled as a temporary implant (< 6-month implantation) but can be used successfully in patients undergoing chemotherapy and/or radiation who require longer implantation.
equivalent between groups. There were no significant differences in the mean number of complication-related surgeries before (p=.79) or after (p=.76) implant, revision surgeries (p=.34), or total surgeries (p=.52). Percentages of patients undergoing at least one complication-related surgery before implant (p=.81), at least one complicationrelated surgery after implant (p=.60), or at least one revision surgery (p=.48) were equivalent.
CONCLUSION:
When comparing patients that completed implant-based reconstruction, combining risk-reducing gynecologic procedures with mastectomy and reconstruction into one OR visit does not appear to negatively impact reconstructive outcomes. Experimental evidence suggests the use of vasopressors has a negative impact on flap survival due to peripheral vasoconstriction, 2,3 but these findings have not been borne out in clinical research. 4, 5 The purpose of this large single institution study was to evaluate the relationship between vasopressor use and breast free flap complications.
Intraoperative Vasopressor Use in

MATERIALS & METHODS:
A retrospective review was conducted of all patients who underwent autologous free flap breast reconstruction between 2000-2017 with a follow-up of greater than one year after surgery. Postoperative flap complications including failure, hematoma, and congestion, as well as other postoperative complications including acute blood loss anemia, pulmonary edema, and number of revision surgeries were recorded.
RESULTS:
A total of 780 autologous breast free flaps were reviewed, with 16 (2.0%), 369 (46.8%) and 291 (36.9%) receiving intraoperative epinephrine, phenylephrine, and ephedrine, respectively. Flap failure was observed in 15 (1.9%), venous thrombosis in 13 (1.6%) and flap congestion in 37 (4.7%) free flaps. Vasopressor use was not associated with flap failure (p = 0.345) or other complications, but was significantly associated with a decreased risk of postoperative flap congestion (p = 0.001). However, in a multivariate analysis, vasopressor use was associated with an increased risk of postoperative acute blood loss anemia (p = 0.012).
CONCLUSION:
Consistent with previous clinical studies, there was no statistical difference in free flap failure between patients who received and did not receive vasopressors intraoperatively. In contrast to previous concerns that vasopressor use compromises flap viability, our study demonstrated intraoperative use of vasopressors was significantly associated with a decreased risk of postoperative flap congestion. These benefits must be balanced with the potential increased risk of postoperative anemia. Further research is necessary to elucidate the optimal type, dosing and schedule of vasopressor administration and which populations may benefit most from intraoperative vasopressor use.
